Canaccord lowered the firm’s price target on Privia Health (PRVA) to $34 from $35 and keeps a Buy rating on the shares. The firm said they posted another solid quarter which portends guidance will likely moove higher considering the company’s high visibility.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Analyst Reiterates Buy on Privia Health as Strong Q1, Robust FCF Conversion, and Diversified Model Support Multi‑Year Growth Outlook
- Privia Health reports Q1 adjusted EPS 19c, consensus 25c
- Privia Health: Buy Rating Reiterated as Analyst Maintains $35 Price Target on Solid Value-Based Care Momentum
- William Blair healthcare IT analysts hold analyst/industry conference call
- Privia Health price target lowered to $26 from $30 at Evercore ISI